University of Leipzig Medical Center Trials

University of Leipzig Medical Center	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Platzbecker, Uwe

TUD-APOLLO-064, NCT02688140 / 2015-001151-68: Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Active, not recruiting

280

Europe

Arsenic trioxide, ATO, Trisenox (R), As2O3, Idarubicin, IDA, Cytarabine, Ara-C, Tretinoin, all-trans retinoic acid, ATRA, Mitoxantrone, MTZ, Mercaptopurine, 6-Mercaptopurine, 6-MP, Methotrexate, MTX

Technische Universität Dresden, Gruppo Italiano Malattie EMatologiche dell'Adulto, Groupe Francophone des Myelodysplasies, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, German Federal Ministry of Education and Research, Teva Pharmaceuticals Europe

Acute Promyelocytic Leukemia

01/25

NCT04712942: Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Completed

Europe

Pevonedistat, Azacitidine

University of Leipzig, Millennium Pharmaceuticals, Inc.

Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease

01/23

PEMAZA, NCT03769532 / 2017-004110-25: MRD-guided Treatment in NPM1mut AML Patients

Recruiting

Europe

Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza®

Technische Universität Dresden, Merck Sharp & Dohme LLC

Acute Myeloid Leukemia

12/25

12/26

IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Active, not recruiting

Europe, RoW

Imetelstat sodium, GRN163L

GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group

Myelodysplastic Syndromes, Acute Myeloid Leukemia

02/25

06/26

LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Terminated

Europe

CA-4948, Emavusertib

University of Leipzig, Curis, Inc.

Myelodysplastic Syndromes, Anemia

07/24

REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting

Europe

RVU120 (SEL120)

GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group

Low Risk Myelodysplastic Syndromes

05/26

05/27

PALOMA, NCT04061239 / 2018-002430-21: Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Recruiting

150

Europe

CPX-351, Vyxeos, Daunorubicin, Cytarabine, Azacitidine, Vidaza

GWT-TUD GmbH

MDS, AML

03/26

09/26

MAGROLIC, NCT05829434: Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Withdrawn

108

Magrolimab, Hu5F9-G4, GS-4721, 7+3, Daunorubicine and Cytarabine, CPX-351, Vyxeos®

Uwe Platzbecker, Gilead Sciences

Acute Myeloid Leukemia, Myelodysplastic Neoplasm

08/28

08/29

APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

1/2

240

Europe, US, RoW

Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine

Aptose Biosciences Inc.

Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia

11/26

04/27

IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting

1/2

218

Europe, US

Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto

AbbVie, Jazz Pharmaceuticals

Acute Myeloid Leukemia

04/26

CA-4948 102, NCT04278768 / 2019-004839-23: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting

1/2

366

Europe, US, RoW

Emavusertib, CA-4948, Venetoclax

Curis, Inc., Curis, Inc

Acute Myelogenous Leukemia, Myelodysplastic Syndrome

04/26

GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed

Europe, RoW

SLN124, Placebo

Silence Therapeutics plc

Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome

05/23

NCT04174547: An European Platform for Translational Research in Myelodysplastic Syndromes

Recruiting

N/A

8670

Europe

Istituto Clinico Humanitas

Myelodysplastic Syndromes

09/21

09/22

GENOMED4ALL, NCT04889729: Improving MDS Classification and Prognosis by AI

Active, not recruiting

N/A

13284

Europe

Istituto Clinico Humanitas

Myelodysplastic Syndromes

12/22

12/24

NCT02192619: National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Recruiting

N/A

500

Europe

observational

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL

12/24

BoHemE, NCT02867085: Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

Completed

N/A

297

Europe

Observational

Technische Universität Dresden

Myelodysplastic Syndromes

08/24

Olavarria, Eduardo L

ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

	Data from ALLELE trial for post-transplant lymphoproliferative disease
	Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease

Recruiting

Europe, Canada, US, RoW

tabelecleucel, tab-cel®, ATA129, EBV-CTL

Atara Biotherapeutics

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications

08/25

06/27

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

ALL-RIC, NCT03821610 / 2017-004800-23: A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission.

Active, not recruiting

242

Europe

Fludarabine, Melphalan, Alemtuzumab, Cyclophosphamide, Mesna, Total Body Irradiation (8Gy)

University of Birmingham

Acute Lymphoblastic Leukemia

11/24

11/27

Franke, Georg-Nikolaus

IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting

210

Europe

MC0518, BAT

medac GmbH

Steroid-refractory Acute Graft-versus-host Disease

08/27

08/30

OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting

225

Europe, Canada, Japan, US, RoW

Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)

F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi

Invasive Aspergillosis

09/25

11/26

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting

440

Europe, RoW

Allogeneic Stem Cell Transplantation

Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)

Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

11/22

11/24

MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting

Europe, US, RoW

GB2064

Galecto Biotech AB, OPIS s.r.l

Myelofibrosis

12/23

06/26

BlastCrisis, NCT03869502: European CML Blast Crisis Register

Recruiting

N/A

250

Europe, RoW

University of Jena

Chronic Myeloid Leukemia in Myeloid Blast Crisis

06/24

TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting

N/A

150

Europe, RoW

No Intervention

Takeda

Cytomegalovirus (CMV)

04/25

Wachter, Rolf

ASPIRE-AF, NCT03968393 / 2019-001336-62: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

Recruiting

2270

Europe, Canada, RoW

Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban

Population Health Research Institute, Hamilton Health Sciences Corporation

Stroke, Atrial Fibrillation

12/26

12/28

NCT00558584: Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy

Completed

N/A

180

Europe, RoW

protein A immunoadsorption, pseudo-immunoadsorption

University Medicine Greifswald, Krupp von Bohlen und Halbach-Foundation, Essen, Germany, ENDI-Foundation, Bad Homburg, Germany, Bristol-Myers Squibb

Dilated Cardiomyopathy

09/21

04/23

NCT04688905: Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)

Active, not recruiting

N/A

Europe

Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion, Cardiac MRI at rest, Echocardiography at rest and with exercise, Spiroergometry, 6 minute walking distance, Right heart catherization at rest and with exercise, Coronary angiography (if not performed within the last year)

University of Leipzig

Dyspnea

08/23

08/24

NCT04963400: Impact of Hospitalization on High-sensitivity Cardiac Troponin T Concentrations Depending on Disease Severity

Completed

N/A

177

Europe

Analysis of hs-cTnT serum concentration at hospitalization, Analysis of hs-cTnT serum concentration after discharge

University of Leipzig

Non-cardiac Disease

01/24

Pilot-CRHF, NCT06269263: Feasibility of Home-based Cardiac Rehabilitation in Patients with Chronic Heart Failure

Recruiting

N/A

Europe

Home-based cardiac rehabilitation

University of Leipzig

Heart Failure

02/25

PVI-SHAM-AF, NCT05119231: Pulmonary Vein Isolation Vs SHAM-pulmonary Vein Isolation for Symptomatic Relief in Patients with AF

Recruiting

N/A

260

Pulmonary Vein Isolation, Sham-Pulmonary Vein Isolation

University of Leipzig

Atrial Fibrillation

06/26

12/26

UNLOAD-HFpEF, NCT05030987: Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction

Recruiting

N/A

Europe

Renal Denervation, Sham, Sham Procedure

University of Leipzig, ReCor Medical, Inc.

Heart Failure With Preserved Ejection Fraction, Hypertension, Renal

12/24

03/26

Find-AF2, NCT04371055: Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

Recruiting

N/A

5200

Europe

7-day Holter ECG, Implantable cardiac monitor, Standard of care

University of Leipzig, Johannes Gutenberg University Mainz

Ischemic Stroke, Atrial Fibrillation

06/26

12/26

Sabri, Osama

LUCAPET, NCT05912465: Predicting Lung Cancer-Associated Cachexia With PET Imaging

Recruiting

N/A

150

Europe

Stress Reduction Training

Medical University of Vienna, University of Leipzig, Careggi Hospital, University of Copenhagen

Cachexia, Lung Neoplasm

07/24

03/25

Kayser, Sabine

DaunoDouble, NCT02140242 / 2013-003191-12: Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

Completed

721

Europe, RoW

study part 1 - dose daunorubicin, induction cycles

Technische Universität Dresden, University Hospital Dresden, Masaryk University

Leukemia, Myelocytic, Acute

04/22

IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting

1/2

218

Europe, US

Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto

AbbVie, Jazz Pharmaceuticals

Acute Myeloid Leukemia

04/26

Robles, Maria Camprubi

OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting

225

Europe, Canada, Japan, US, RoW

Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)

F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi

Invasive Aspergillosis

09/25

11/26

NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting

322

Europe, Canada, US

Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF

Arog Pharmaceuticals, Inc.

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

10/24

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated

1/2

Europe, US

Lanraplenib, LANRA, Gilteritinib, XOSPATA®

Kronos Bio, Kronos Bio, Inc.

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

04/24

AFM28-101, NCT05817058: First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

Europe

AFM28

Affimed GmbH

Acute Myeloid Leukemia

03/25

03/26

LESAS, NCT04305314: Long-term Enlarged Survival After an Enhanced Recovery Protocol ().

Recruiting

N/A

750

Europe

PRI (Enhanced Recovery after surgery protocol)

Grupo Español de Rehabilitación Multimodal, Instituto de Salud Carlos III, Instituto de Investigación Sanitaria Aragón

Major Surgery

09/22

09/25

NCT04737785: Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

Completed

N/A

252

Europe, RoW

European Society for Blood and Marrow Transplantation

Central Nervous System Infections, Central Nervous System Complication, Infectious Disease of Nervous System, Blood Disease, Blood Cancer, Infection

06/23

08/24

Paviglianiti, Annalisa

ARES, NCT04769895 / 2021-001841-11: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Active, not recruiting

Europe

MaaT013

MaaT Pharma, MaaT Pharma

Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

11/24

11/25

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

López, Estefanía Pérez

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

Gonalez-Sierra, Pedro

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

Ochando, Melisa Karina Torres

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

Karppinen, Atte

NCT02300766: Cerebellar Mutism Syndrome Study

Recruiting

N/A

1000

Europe, RoW

Rigshospitalet, Denmark, Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital, Technical University of Denmark, Karolinska University Hospital, Skane University Hospital, University Hospital, Linkoeping, Uppsala University Hospital, Sahlgrenska University Hospital, Sweden, University Hospital, Umeå, Oslo University Hospital, Trondheim University Hospital, Haukeland University Hospital, University Hospital of North Norway, Helsinki University Central Hospital, Tampere University Hospital, Kuopio University Hospital, Turku University Hospital, Oulu University Hospital, Radboud University Medical Center, Liverpool University Hospitals NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, Nottingham University Hospitals NHS Trust, University Hospital Birmingham, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Infirmary of Edinburgh, South Glasgow University Hospitals NHS Trust, University Hospital Tuebingen, Medical University of Vienna, Ospedale Pediatrico Bambin Gesù, Motol University Hospital, University of Leipzig Medical Center, Universitaire Ziekenhuizen KU Leuven, Queen Fabiola Children's University Hospital, Cliniques universitaires Saint-Luc, University Hospital, Ghent, Hospital De La Citadelle, CHC MontLégia, University Hospital, Antwerp

Infratentorial Neoplasms, Mutism

12/28

PI, Marta Pena new

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25

Rodriguez_Chinea, Anabelle

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/25



	Diseases Companies Products Productz Mechanisms of Action Sites